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Abstract: The Critical Path to Tuberculosis Drug Regimens (CPTR) initiative aims to support the rational deployment of new 
tuberculosis (TB) therapies by speeding the development and impact of new and markedly improved drug regimens as well as rapid 
drug susceptibility tests. Co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance in 2010, 
CPTR is a coalition comprising the world’s leading pharmaceutical companies, product development sponsors, diagnostic companies, 
regulatory agencies, and civil society organizations which support and catalyze advances in regulatory science, the development of 
infrastructure, and other progress needed to accelerate the pace of development and introduction of novel regimens and rapid drug 
susceptibility tests. This manuscript summarizes the work of two subgroups within CPTR, the Regulatory Sciences and Rapid Drug 
Susceptibility Test consortia, and their efforts to drive innovation. These consortia are supported by a robust TB clinical data platform, 
which continues to evolve through contributions of contemporary TB clinical trial data sets as well as whole genome sequence level 
data from isolates across the globe. Examples of innovation are described and include a recently-qualified drug development tool and 
emerging programs to support the development of clinical trial simulation tools. 
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1. The Need for Novel, Safer and Faster-acting 
TB Drug Regimens and Rapid Drug Suscepti-
bility Tests for Tuberculosis 
s of 2015, tuberculosis (TB) remains the 
world’s single most deadly infectious disease 
impacting one-third of the population. TB 
claims 1.5 million lives annually, despite the fact that 
therapies have been available for more than four de-
cades[1]. Current standard of care treatment paradigms 
face major challenges due to (1) long duration of 
treatment (9 months to 2 years depending on suscep-
tibility profiles); (2) serious adverse drug reactions 
(magnified with concomitant therapies for HIV); and 
(3) the emergence of drug resistance. Despite the 
availability of therapies, patient treatment is frequent-
ly not optimized due to the difficulty in determining if 
the mycobacteria are susceptible to the four-drug 
cocktail that was prescribed. Therefore, rapid drug 
susceptibility tests (RDSTs) are required to improve 
the management of TB patients, support the rational 
use of new TB drug regimens, and increase under- 
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standing of the global burden of drug-resistant TB. 
Despite the need to optimize TB therapy and suscepti-
bility testing, drug and diagnostic innovation has been 
stagnant for many decades, driven largely by the low 
return on investment and the existence of therapies 
that were deemed sufficient. This stagnation was un-
acceptable to many in the global health community 
bringing about a tidal shift in thinking. As a result, a 
few existing antibiotic classes (such as nitroimida-
zoles and oxazolidinones) have emerged with the po-
tential to serve as new and more effective combination 
partners for the treatment of TB. 
2. The Opportunity for Global Collaborative 
Partnership 
An evaluation of the TB drug development landscape, 
regulatory environment and global implementation 
plan highlighted key areas where innovation would be 
required to successfully advance entirely new drug 
regimens in an efficient manner. A novel regimen is 
critical for many reasons including the need for de-
creased drug–drug interactions, optimization of dosing 
of individual components and shorter treatment dura-
tion to increase patient compliance compared to cur-
rent standard of care. Additionally, an optimized stan-
dard treatment approach can be linked with standar-
dized testing for TB. First and foremost, optimized 
paradigms for early clinical testing of novel combina-
tion regimens and supporting regulatory strategies 
would be critical. 
In 2010, the CPTR consortium[2] was launched to 
address these key gaps in innovation, acknowledging 
the need for a cross-sector collaborative approach. This 
global partnership, led by the Bill & Melinda Gates 
Foundation, TB Alliance and the Critical Path Institute, 
was initially designed to accelerate novel TB drug 
regimen development as well as global regulatory 
processes to support speed to innovation. Founding 
partners include representatives from the pharmaceu-
tical sector (Janssen, Pfizer, AstraZeneca, Sequella, 
Otsuka), the government sector (US Centers for Dis-
ease Control, US National Institutes Allergy and Infec-
tious Diseases) the non-profit sector (TB Alliance), 
patient advocacy groups (Treatment Action Group), 
the World Health Organization (WHO), the academic 
sector, and Regulatory Health Authorities (European 
Medicines Agency (EMA) and the US Food and Drug 
Administration (FDA). The operational design of the 
consortium is intended to drive key areas of innova-
tion addressed through working groups consisting of 
subject matter experts representing each sector and 
stakeholder group (Figure 1). 
 
 
 
Figure 1. CPTR working group model. 
 
For purposes of this manuscript, we will focus on 
the efforts of the Regulatory Sciences and Rapid Drug 
Susceptibility Testing consortia within CPTR, given 
their emphasis on scientific and regulatory innovation. 
Other CPTR consortia which will not be discussed 
here include the Research Resources Consortium, 
which is keenly focused on critical parallel issues such 
as TB Clinical Trial Infrastructure and the Access and 
Appropriate Use and Community Engagement efforts. 
3. The CPTR Regulatory Sciences Consortium 
3.1 Decreasing Risk and Increasing Confidence in 
TB Drug Regimen Development  
The working group projects led by the CPTR Regula-
tory Sciences Programs are focused on de-risking 
critical decision points as part of the TB regimen de-
velopment process. These efforts include the valida-
tion of new drug development tools, increasing confi-
dence in biomarkers for TB, and the development of 
TB clinical trial modeling tools for better trial design 
through simulation. Each of these programs is enabled 
by the CPTR TB clinical trial data platform that in-
cludes critical data contributions by, among others, 
Janssen, CDC, and the TB Alliance. These contempo-
rary clinical trial data sets have been mapped to the 
Clinical Data Interchange Standards Consortium 
(CDISC) TB Data Standard[3], allowing the data to be 
aggregated for more informed statistical analysis. The 
TB data standard was developed as part of the CPTR 
Regulatory Sciences team efforts in partnership with 
CDISC. This data standard was a fundamental enabler 
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to the data aggregation required to develop our inno-
vative drug development tools and achieve modeling 
and simulation goals. Several of the programs driven 
by the CPTR regulatory sciences project teams are 
summarized below. 
3.2 The in vitro Hollow Fiber Model System for 
Tuberculosis (HFS-TB) as a Translational Model 
Between Pre-clinical and Early Clinical Drug De-
velopment Stage Gates 
Anti-TB drug regimen development strategies will be 
greatly enhanced using validated, reliable pre-clinical 
data that support the informed selection of each new 
entity to be tested in early combination studies. 
Beyond compound selection, quantitative pharmaco-
kinetic and pharmacodynamic (PK/PD) information is 
needed to support informed dose selection for those 
early clinical combination regimens. In addition, 
non-clinical novel methodologies and drug develop-
ment tools (DDTs) with demonstrated predictive ac-
curacy for clinical and microbial outcomes are needed 
to support effective drug development decision-making. 
Endorsement of these DDTs by regulatory authorities 
is critical for drug developers as it promotes con-
fidence in their use and supports incorporation of data 
generated by these DTTs in Investigational New Drug 
(IND)/Clinical Trial Authorization (CTA) and Mar-
keting Authorization Application (MAA)/New Drug 
Application (NDA) filings. The in vitro hollow fiber 
system of tuberculosis (HFS-TB) is a DDT that can 
support these needs by providing a quantitative 
PK/PD understanding of new TB drugs and regimens. 
These data used in partnership with other preclinical 
data can support and expedite selection of more opti-
mized regimens. 
The HFS-TB is able to recapitulate concentra-
tion–time profiles (exposure) observed in patients for 
a single drug, as well as for multiple drugs tested in 
combination. The HFS-TB model (Figure 2) consists 
of a peripheral or pharmacodynamic compartment for 
the Mycobacterium tuberculosis inoculum and a cen-
tral drug-containing or pharmacokinetic compartment. 
The hollow fibers are semipermeable fiber bundles 
with pores of different molecular-weight cutoffs that 
are encased in a plastic cartridge. Drugs are admini-
stered to the central compartment via a syringe pump 
which is programmed to mimic desired peak concen-
tration and time to peak concentration encountered in 
patients. The drug(s) diffuse across the hollow fibers 
into and out of the peripheral compartment via first- 
order kinetic principles. The HFS-TB can be used to  
 
 
 
Figure 2. In vitro HFS-TB model. 
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mimic a single drug profile or combination drug pro-
file in the central compartment with a half-life that 
mimics that encountered in lungs of patients. Myco-
bacterium tuberculosis cells are too big to pass into 
the central compartment and thus are confined to the 
peripheral compartment.  
The HFS-TB supports the evaluation of such drug 
exposures for the ability to kill M. tuberculosis in a 
variety of physiological conditions. This quantitative 
output can be used to inform the selection of optimal 
drug exposures, drug doses, susceptibility breakpoints, 
and optimal combination regimens in patients, and to 
inform the design of nonclinical experiments in 
animal models, based on Monte Carlo simulations.  
The Pre-Clinical and Clinical Sciences Working 
Group within CPTR executed an evidence-based 
evaluation of the predictive accuracy of the HFS-TB 
to validate this model as a novel DDT. This extensive 
effort was enabled through the collaborative efforts of 
subject matter experts representing the pharmaceutical 
industry, academia, product development partnerships, 
and regulatory authorities including the FDA and the 
EMA. This team developed a comprehensive analysis 
plan following the regulatory guidance documents for 
novel methodology/DDT qualification and engaged in 
discussions with the FDA and the EMA.  
In order to pursue regulatory endorsement for the 
HFS-TB as a DDT, the results from the quantitative 
predictive accuracy analyses were submitted to both 
the FDA and EMA. The findings were presented to the 
FDA via the voluntary exploratory data submission 
mechanism. The findings were also presented to the 
EMA via the qualification advice mechanism through 
EMA’s Scientific Advice Working Party (SAWP) 
which led to a qualification opinion mechanism by 
EMA’s Committee for Medicinal Products for Human 
Use (CHMP). EMA issued a qualification opinion for 
the HFS-TB[4] and the FDA has described its utility as 
part of the updated guidance on TB drug development. 
Qualification and other mechanisms of regulatory as-
sessment for new DDTs and biomarkers increase the 
pharmaceutical industry’s confidence in implementa-
tion of the tools and biomarkers as part of the drug 
development process for new drugs. In addition, the 
decreased review times when qualified tools or bio-
markers are used as part of their supporting data for 
new INDs and CTAs, provide tangible benefits for 
drug developers (Figure 3). 
Clinical trials for new tuberculosis drugs and drug 
regimens are long in duration and very costly. There 
are several opportunities to increase confidence in the 
transition between key development phases by im-
proving understanding of the PK/PD relationships and 
translation as well as developing robust clinical trial 
simulation tools that can improve the design of clini-
cal trials. CPTR has undertaken a number of collabor-
ative projects to increase confidence in the tuberculo-
sis drug development process as noted in Figure 4.  
3.3 Physiologically-Based Pharmacokinetic (PBPK) 
Model for Evaluating Systemic Drug Distribution 
in the Mycobacterium Tuberculosis-Infected Lung 
There is a need to better understand the distribution of 
anti-TB therapeutics into lung tissue and lung lesions 
caused by this disease. PBPK modeling captures the 
complex mechanistic drug distribution processes in 
the infected, inflamed, and damaged lung with the 
goal of improving treatment and regimen selection 
designed to optimize drug exposures across the hete-
rogeneous sites of action in the lung[5]. Accordingly, 
the CPTR modeling and simulation workgroup, part 
of the Regulatory Sciences Consortium, partnered 
with SimCyp to develop a PBPK model describing the 
TB-infected lung in a virtual South African population. 
This model is based on compound files for standard- 
 
 
 
Figure 3. Drug development tool evaluation process. 
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Figure 4. Opportunities to improve tuberculosis drug development paradigm. 
 
of-care drugs and is implemented on the SimCyp 
platform. This team is working on refinements to the 
model, which will include sub-compartments that de-
scribe drug penetration into granulomas, and com-
pound files for newer anti-TB drugs.  
3.4 Population Pharmacokinetic and Pharmaco-
dynamic (PK/PD) Model Derived From Therapeu-
tic Monitoring Data 
A significant challenge to developing better clinical 
trial simulation tools for TB is the lack of clinical trial 
data, especially trials that include PK/PD assess-
ments[6–8]. Therefore, the CPTR Regulatory Sciences 
Consortium is spearheading an effort with our Univer-
sity of Florida partner, which will utilize PK/PD data 
where therapeutic drug monitoring was practiced. This 
work will help determine if dose adjustments of an-
ti-TB therapy resulted in different outcomes for each 
of the first- and second-line TB drugs, along with re-
levant patient data (covariates). This will allow the 
exploration of relationships between PK estimates and 
clinical outcomes of both efficacy and toxicity strati-
fied by the regimens used (particularly for multi-drug 
resistant (MDR) TB). The results from this effort will 
be compared to and contrasted with existing guide-
lines for similar clinical scenarios. 
3.5 Evaluation of the Liquid Culture Biomarker to 
Inform the Development of Tuberculosis Modeling 
and Simulation Tools  
There is a need for quantitative tools to more accu-
rately evaluate efficacy in Phase II clinical trials for 
combination TB regimens and to more reliably predict 
clinically relevant endpoints for Phase III clinical tri-
als, based on early efficacy evaluations during Phase 
II[9,10]. To meet this goal, the CPTR Regulatory 
Sciences Consortium, in collaboration with our Phar-
sight partner, will assess the longitudinal changes in 
time to positivity (TTP) and its relevant sources of 
variability as a continuous measure in TB patients. In 
addition, a quantitative model linking changes in TTP 
from liquid culture to durable cure will be devel-
oped[11]. Simulations of longitudinal TTP data will be 
performed in sub-populations of interest and the re-
sulting effect on durable cure will be determined. 
3.6 Mechanism-Based Systems Pharmacology 
Model for Tuberculosis 
New TB drugs and therapy combinations require 
lengthy, expensive clinical trials. Traditional in vitro 
or in vivo murine models are rarely able to represent 
unique aspects of TB disease and pathology, such as 
granuloma formation, bacterial resistance, patient 
non-adherence, or comorbid diseases[12]. Therefore, 
the CPTR Regulatory Sciences Consortium is devel-
oping a novel systems pharmacology model in order 
to establish a TB simulation (TB sim) framework in-
corporating mechanism of action for multiple anti-TB 
agents, pharmacokinetic and bactericidal properties of 
drugs, drug dosing and duration, granuloma dynamics, 
risk of bacterial resistance, immune response, and 
clinically relevant outcomes at a population level. 
Model parameters will be based on relevant in vitro 
and in vivo animal experiments, data emerging from 
multiple CPTR workgroups, emerging clinical trial 
results, ongoing systems biology efforts, and bio-
marker work. As the simulation model framework 
matures, the goal is to establish predictive metrics of 
in vitro and in vivo animal models and emerging bio-
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markers for TB. The TB sim model will also be used 
to explore enhanced clinical trial designs which could 
shorten clinical development time, and for assessment 
of specific patient populations. 
3.7 QT Risk Assessment and Interpretation in TB 
Drug Development 
QT prolongation has been observed with many of the 
drugs used to treat TB. However, the clinical 
risk/benefit and differentiation between TB combina-
tion regimens with respect to QT prolongation is un-
clear[13,14]. This project, led by the CPTR Regulatory 
Sciences Consortium, in collaboration with Pharsight, 
aims to (1) collate historical data with TB drugs alone 
and in combination pertaining to QT effects and asso-
ciated clinical outcomes (e.g., Torsade de pointes, 
sudden death, hospitalization) and (2) provide guid-
ance/recommendations on suitable experimental de-
signs (in vitro, preclinical, and clinical), data analyti-
cal approaches, signal interpretation, and go/no go 
decision criteria related to QT prolongation in the 
context of new TB drug combination development. 
4. The CPTR Rapid Drug Susceptibility Testing 
Consortium 
4.1 The Need for RDSTs for Tuberculosis 
RDSTs are needed to improve the management of TB 
patients, to facilitate drug development and rational 
use of new TB drug regimens, and to better under-
stand the global burden of drug-resistant TB. The field 
has recognized the need for a data-sharing platform 
that provides a one-stop data source for clinically re-
levant genotypic and phenotypic information on MTB. 
Having such data reviewed and validated, and made 
accessible in one place, would support the develop-
ment of new RDSTs that can quickly inform appropri-
ate therapy for TB patients. A comprehensive, curated, 
and easy-to-use data platform of this scope does not 
currently exist and is a major barrier to the under-
standing of the relationship between genetic mutations 
and drug resistance in MTB. This barrier impacts drug 
and diagnostic developers, clinicians prescribing 
therapy, and ultimately patients who should have ear-
lier access to appropriate drug regimens. Successful 
execution of such an extensive database platform re-
quires substantial collaboration from scientists inves-
tigating the genetic basis for drug resistance world-
wide, and from developers with expertise in database 
design and implementation ensuring quality and secu-
rity, while providing assurance that all relevant legal, 
patient data privacy, and intellectual property stan-
dards are met. The CPTR Rapid Drug Susceptibility 
Testing Consortium can provide the means to accom-
plish this goal. 
4.2 The Opportunity to Leverage the CPTR Colla-
boration to Ensure Rational Implementation and 
Deployment of New Tuberculosis Drug Regimens 
Through Development of Rapid Drug Susceptibili-
ty Tests 
With two new drugs recently receiving conditional 
approval (bedaquiline and delamanid), the off-label 
use of drugs in TB treatment regimens (linezolid and 
clofazamine), and drugs being used in TB treatment 
regimens despite having no TB label claims, clinical 
trials are underway to test new combinations of these 
and other existing drugs that may prove to be safer 
and more effective, and allow for shorter treatment 
duration. If these new treatment regimens prove to be 
superior to the standard of care, they will be widely 
adopted by global public healthcare programs and will 
require improved and novel RDSTs in order to effec-
tively implement them. In addition, the inclusion of 
new drugs could potentially unify treatment for pa-
tients with drug-susceptible infections, as well as for 
an increasing number of patients who are infected 
with drug-resistant strains of MTB, or who develop 
drug resistance during therapy. However, treatment 
without identifying drug susceptibility runs the risk of 
employing suboptimal drug regimens with fewer ef-
fective drugs. As a small number of TB isolates may 
be naturally resistant, these new drug regimens may 
exert selection pressure that could favor the survival 
and transmission of drug-resistant strains. Therefore, 
vigilance is required to quickly identify patients who 
harbor drug-resistant TB, map the trajectory of drug 
resistance in the population, and develop alternatives 
to ensure the new drug armaments remain effective. 
4.3 Evolution of the Relational Sequencing Data 
Platform (ReSeqTB) Project 
Currently, the correlation between MTB genotypic 
data and TB drug resistance is widely dispersed 
among multiple MTB sequence databases, both pri-
vate and public. Meta-analysis of these divergent pub-
lished data sets has highlighted gaps and discrepancies 
in our knowledge, as well as bias that may be present 
because geographic strain diversity is not well 
represented. These findings highlight the need for a 
universally harmonized database platform that is 
widely accessible and user friendly. With sufficient 
numbers of globally-derived MTB whole genome se-
quences, such a statistically powered database plat-
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form could robustly facilitate the clinical interpreta-
tion of different genetic polymorphisms. Test devel-
opers could then rely on such clinically validated ge-
nome sequence interpretations and confidently acce-
lerate development of RDSTs for both current and 
newly emerging TB drugs and drug regimens. To get 
there, however, thousands of genomic sequences sub-
ject to robust quality checks will need to be sourced 
from multiple global researchers to account for strain 
variation. In addition, data sets will need to be curated 
to provide the highest possible confidence in clinical 
interpretation to support assessment and informed de-
cision making. To accomplish this, CPTR and the 
Foundation for Innovative New Diagnostics (FIND) 
secured funding from the Bill & Melinda Gates Found-
ation and have partnered with the New Diagnostics 
Working Group, WHO, Centers for Disease Control 
(CDC), and the National Institute of Allergy and In-
fectious Disease (NIAID) to develop a platform that 
supports evidence-based assessment of drug mutations 
in MTB for diagnostic, research and eventually clini-
cal application. The ReSeqTB database platform, cur-
rently in development by CPTR, will serve as a single 
globally-harmonized repository for the compilation, 
curation, and validation of existing and newly created 
data on TB drug resistance correlations (Figure 5). 
 
 
 
Figure 5. ReSeqTB collaborative partnership. 
 
5. Conclusion 
Novel TB drug regimens which are safer and more 
efficacious and have a shorter duration of treatment 
than the current standard of care are critically needed. 
Just as important is the need for accompanying RDSTs 
to support their usage and protect the durability of 
new drugs and regimens. Regulatory and scientific 
innovations supporting these endeavors represent 
cross-sector collaboration and the secure sharing of 
data and information sufficient to validate the imple-
mentation of new drug development tools as well as 
the evidence-based development of useful modeling 
and simulation tools to refine the design of TB clinical  
trials, key stage gates and modernize the approach to 
regimen development. Additionally, aggregated data 
representative of global clinical experience support the 
evidence-based development of novel assays for TB 
RDSTs. The CPTR consortium represents a successful 
partnership model that continues to produce mea-
ningful outcomes that will be made publicly available 
for use and implementation. 
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